早期唇鳞状细胞癌（lip SCC）可采用常规切除、Mohs微创手术（MMS）或放射治疗。本回顾性研究旨在描述这些治疗的医疗结果、患者报告的结果和成本。 回顾性队列研究纳入了1996年至2019年期间接受治疗的T1-T2期唇鳞状细胞癌患者。医疗结果、复发率和生存率从病历中获取。利用Face-Q H&N和EQ-5D-5L问卷评估面部外观、面部功能和生活质量（QoL）。同时计算了治疗的成本。 在336例唇鳞状细胞癌中，122例采用切除术治疗、139例采用MMS治疗，75例采用放射治疗。局部复发率为2.7%，区域复发率为4.8%。疾病相关死亡率为2%。T2期和肿瘤分化差与复发相关。治疗后的QoL、面部功能和外观评价良好。放射治疗是最昂贵的治疗方式。 早期唇鳞状细胞癌预后良好，经过36个月的中位随访，疾病特异性生存率达到98.2%，远期随访显示高生活质量和满意度。基于成本和局部区域复发风险，我们认为，对于大多数非复杂唇鳞状细胞癌，MMS将是最合理的治疗选择。 © 2023 作者版权所有。Oral Diseases由Wiley Periodicals LLC出版。

Early stage lip squamous cell carcinoma (lip SCC) can be treated with conventional excision, Mohs micrographic surgery (MMS), or brachytherapy. The aim of this retrospective study was to describe the medical outcomes, patient-reported outcomes, and costs of these treatments.A retrospective cohort study of T1-T2 lip SSCs treated between 1996 and 2019. Medical outcomes, recurrences, and survival were retrieved from medical records. Facial appearance, facial function, and Quality of Life (QoL) were measured with the Face-Q H&N and EQ-5D-5L questionnaires. Costs were also calculated.Of the 336 lip SCCs, 122 were treated with excision, 139 with MMS, and 75 with brachytherapy. Locally, the recurrence rate was 2.7% and regionally 4.8%. There were 2% disease-related deaths. T2-stage and poor tumor differentiation were associated with recurrences. Posttreatment QoL, facial function, and appearance were rated as good. Brachytherapy was the most expensive treatment modality.Early-stage lip SCC has a good prognosis, with a disease-specific survival of 98.2% after a median follow-up of 36 months, there was a high QoL and satisfaction at long-term follow-up. Based on the costs and the risk of locoregional recurrences, we believe that, for most noncomplex lip SCCs, MMS would be the most logical treatment option.© 2023 The Authors. Oral Diseases published by Wiley Periodicals LLC.